Youngseon Byeon
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.
Journal: Cancer research communications
Published: April 04, 2024
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.
Journal: Frontiers in immunology
Published: November 10, 2023
YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment.
Journal: Frontiers in chemistry
Published: July 19, 2022
Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Journal: Journal for immunotherapy of cancer
Published: January 30, 2022
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.
Journal: Frontiers in oncology
Published: November 24, 2021
Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor.
Journal: Yonsei medical journal
Published: September 09, 2021
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models.
Journal: Clinical & translational immunology
Published: February 17, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026